Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism.

Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D.

Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760. [Epub ahead of print]

PMID:
29844011
2.

JAK2 and JMJD1C activate NFE2 in MPNs.

Crispino JD.

Blood. 2018 May 3;131(18):1998-1999. doi: 10.1182/blood-2018-03-839779. No abstract available.

PMID:
29724716
3.

Survey and evaluation of mutations in the human KLF1 transcription unit.

Gnanapragasam MN, Crispino JD, Ali AM, Weinberg R, Hoffman R, Raza A, Bieker JJ.

Sci Rep. 2018 Apr 26;8(1):6587. doi: 10.1038/s41598-018-24962-3.

4.

ANP32A regulates histone H3 acetylation and promotes leukemogenesis.

Yang X, Lu B, Sun X, Han C, Fu C, Xu K, Wang M, Li D, Chen Z, Opal P, Wen Q, Crispino JD, Wang QF, Huang Z.

Leukemia. 2018 Jul;32(7):1587-1597. doi: 10.1038/s41375-018-0010-7. Epub 2018 Feb 2.

PMID:
29467488
5.

GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Ling T, Crispino JD, Zingariello M, Martelli F, Migliaccio AR.

Expert Rev Hematol. 2018 Mar;11(3):169-184. doi: 10.1080/17474086.2018.1436965. Epub 2018 Feb 19.

PMID:
29400094
6.

ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia.

Sun X, Lu B, Han C, Qiu W, Jin Q, Li D, Li Q, Yang Q, Wen Q, Opal P, Kini AR, Crispino JD, Huang Z.

Blood Cancer J. 2017 Dec 22;7(12):661. doi: 10.1038/s41408-017-0031-x. No abstract available.

7.

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.

Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD.

EBioMedicine. 2017 Dec;26:112-125. doi: 10.1016/j.ebiom.2017.11.013. Epub 2017 Nov 21.

8.

Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.

Zhao B, Mei Y, Cao L, Zhang J, Sumagin R, Yang J, Gao J, Schipma MJ, Wang Y, Thorsheim C, Zhao L, Stalker T, Stein B, Wen QJ, Crispino JD, Abrams CS, Ji P.

J Clin Invest. 2018 Jan 2;128(1):125-140. doi: 10.1172/JCI94518. Epub 2017 Nov 20.

9.

Cohesin Mutations in Myeloid Malignancies.

Fisher JB, McNulty M, Burke MJ, Crispino JD, Rao S.

Trends Cancer. 2017 Apr;3(4):282-293. doi: 10.1016/j.trecan.2017.02.006. Review.

10.

The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature.

Zingariello M, Sancillo L, Martelli F, Ciaffoni F, Marra M, Varricchio L, Rana RA, Zhao C, Crispino JD, Migliaccio AR.

Blood Cancer J. 2017 Jun 16;7(6):e572. doi: 10.1038/bcj.2017.51.

11.

The mitochondrial respiratory chain is essential for haematopoietic stem cell function.

Ansó E, Weinberg SE, Diebold LP, Thompson BJ, Malinge S, Schumacker PT, Liu X, Zhang Y, Shao Z, Steadman M, Marsh KM, Xu J, Crispino JD, Chandel NS.

Nat Cell Biol. 2017 Jun;19(6):614-625. doi: 10.1038/ncb3529. Epub 2017 May 15.

12.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

13.

Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.

Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, Iancu-Rubin C.

Leukemia. 2017 Nov;31(11):2458-2467. doi: 10.1038/leu.2017.78. Epub 2017 Mar 8.

14.

Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD.

J Clin Invest. 2017 Apr 3;127(4):1316-1320. doi: 10.1172/JCI82905. Epub 2017 Feb 27.

15.

GATA factor mutations in hematologic disease.

Crispino JD, Horwitz MS.

Blood. 2017 Apr 13;129(15):2103-2110. doi: 10.1182/blood-2016-09-687889. Epub 2017 Feb 8. Review.

16.

Not All H3K4 Methylations Are Created Equal: Mll2/COMPASS Dependency in Primordial Germ Cell Specification.

Hu D, Gao X, Cao K, Morgan MA, Mas G, Smith ER, Volk AG, Bartom ET, Crispino JD, Di Croce L, Shilatifard A.

Mol Cell. 2017 Feb 2;65(3):460-475.e6. doi: 10.1016/j.molcel.2017.01.013.

17.

Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom ET, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, Shilatifard A.

Cell. 2017 Jan 12;168(1-2):59-72.e13. doi: 10.1016/j.cell.2016.12.011. Epub 2017 Jan 5.

18.

Kinase signaling and targeted therapy for primary myelofibrosis.

Yang Q, Crispino JD, Wen QJ.

Exp Hematol. 2017 Apr;48:32-38. doi: 10.1016/j.exphem.2016.12.007. Epub 2016 Dec 30. Review.

19.

The Hippo-p53 pathway in megakaryopoiesis.

Suraneni PK, Crispino JD.

Haematologica. 2016 Dec;101(12):1446-1448. No abstract available.

20.

Novel function of FAXDC2 in megakaryopoiesis.

Jin Q, Ren Y, Wang M, Suraneni PK, Li D, Crispino JD, Fan J, Huang Z.

Blood Cancer J. 2016 Sep 30;6(9):e478. doi: 10.1038/bcj.2016.87.

21.

Signaling a link between interferon and the traits of Down syndrome.

Kirsammer G, Crispino JD.

Elife. 2016 Sep 6;5. pii: e20196. doi: 10.7554/eLife.20196.

22.

The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9.

Fisher JB, Peterson J, Reimer M, Stelloh C, Pulakanti K, Gerbec ZJ, Abel AM, Strouse JM, Strouse C, McNulty M, Malarkannan S, Crispino JD, Milanovich S, Rao S.

Leukemia. 2017 Mar;31(3):712-719. doi: 10.1038/leu.2016.240. Epub 2016 Aug 24.

23.

The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.

Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD.

Leukemia. 2016 Sep;30(9):1816-23. doi: 10.1038/leu.2016.164. Epub 2016 Jun 10. Review.

24.

Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.

Yu C, Yang Q, Chen Y, Wang D, Levine R, Crispino J, Wen Q, Huang Z.

Cell Biosci. 2016 May 23;6:34. doi: 10.1186/s13578-016-0097-3. eCollection 2016.

25.

iPSCs Offer a New Look at GATA1-Trisomy 21 Cooperation.

McNulty M, Crispino JD.

Cell Stem Cell. 2016 May 5;18(5):563-4. doi: 10.1016/j.stem.2016.04.007.

26.

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD.

Nat Med. 2015 Dec;21(12):1473-80. doi: 10.1038/nm.3995. Epub 2015 Nov 16.

27.

An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference.

Blobel GA, Bodine D, Brand M, Crispino J, de Bruijn MF, Nathan D, Papayannopoulou T, Porcher C, Strouboulis J, Zon L, Higgs DR, Stamatoyannopoulos G, Engel JD.

Exp Hematol. 2015 Oct;43(10):821-37. doi: 10.1016/j.exphem.2015.06.008. Epub 2015 Jul 2. Review.

28.

The role of the chromatin assembly complex (CAF-1) and its p60 subunit (CHAF1b) in homeostasis and disease.

Volk A, Crispino JD.

Biochim Biophys Acta. 2015 Aug;1849(8):979-86. doi: 10.1016/j.bbagrm.2015.05.009. Epub 2015 Jun 9. Review.

29.

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.

Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, Besson T, Leblond B, Désiré L, Malinge S, Crispino JD.

J Exp Med. 2015 Jun 1;212(6):953-70. doi: 10.1084/jem.20150002. Epub 2015 May 25.

30.

Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression.

Chlon TM, McNulty M, Goldenson B, Rosinski A, Crispino JD.

Haematologica. 2015 May;100(5):575-84. doi: 10.3324/haematol.2014.112714. Epub 2015 Feb 14.

31.

Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation.

Goldenson B, Kirsammer G, Stankiewicz MJ, Wen QJ, Crispino JD.

Blood. 2015 Mar 26;125(13):2141-50. doi: 10.1182/blood-2014-12-615401. Epub 2015 Feb 10.

32.

Targeting novel signaling pathways for resistant acute myeloid leukemia.

Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA.

Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5. Review.

33.

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.

Shaham L, Vendramini E, Ge Y, Goren Y, Birger Y, Tijssen MR, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, Göttgens B, Crispino JD, Taub JW, Izraeli S.

Blood. 2015 Feb 19;125(8):1292-301. doi: 10.1182/blood-2014-06-581892. Epub 2014 Dec 22. Erratum in: Blood. 2016 Apr 21;127(16):2042.

34.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

35.

Erythro-megakaryocytic transcription factors associated with hereditary anemia.

Crispino JD, Weiss MJ.

Blood. 2014 May 15;123(20):3080-8. doi: 10.1182/blood-2014-01-453167. Epub 2014 Mar 20. Review.

36.

The aurora kinases in cell cycle and leukemia.

Goldenson B, Crispino JD.

Oncogene. 2015 Jan 29;34(5):537-45. doi: 10.1038/onc.2014.14. Epub 2014 Mar 17. Review.

37.

PSTPIP2 dysregulation contributes to aberrant terminal differentiation in GATA-1-deficient megakaryocytes by activating LYN.

Liu L, Wen Q, Gong R, Gilles L, Stankiewicz MJ, Li W, Guo M, Li L, Sun X, Li W, Crispino JD, Huang Z.

Cell Death Dis. 2014 Jan 9;5:e988. doi: 10.1038/cddis.2013.512.

38.

Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.

Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME.

Blood. 2013 Oct 3;122(14):e33-43. doi: 10.1182/blood-2013-05-503011. Epub 2013 Aug 26.

39.

Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.

Krause DS, Crispino JD.

Clin Cancer Res. 2013 Nov 15;19(22):6084-8. doi: 10.1158/1078-0432.CCR-12-2604. Epub 2013 Aug 20.

40.

Onset of rosette formation during spontaneous neural differentiation of hESC and hiPSC colonies.

Malchenko S, Xie J, de Fatima Bonaldo M, Vanin EF, Bhattacharyya BJ, Belmadani A, Xi G, Galat V, Goossens W, Seftor RE, Tomita T, Crispino J, Miller RJ, Bohn MC, Hendrix MJ, Soares MB.

Gene. 2014 Jan 25;534(2):400-7. doi: 10.1016/j.gene.2013.07.101. Epub 2013 Aug 15.

41.

AKT is a therapeutic target in myeloproliferative neoplasms.

Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD.

Leukemia. 2013 Sep;27(9):1882-90. doi: 10.1038/leu.2013.167. Epub 2013 Jun 10.

42.

Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.

Lasho T, Johnson SH, Smith DI, Crispino JD, Pardanani A, Vasmatzis G, Tefferi A.

Am J Hematol. 2013 Sep;88(9):741-6. doi: 10.1002/ajh.23495. Epub 2013 Aug 1.

43.

Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.

Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM.

Oncogene. 2014 Apr 24;33(17):2169-78. doi: 10.1038/onc.2013.169. Epub 2013 Jun 3.

44.

Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Birger Y, Goldberg L, Chlon TM, Goldenson B, Muler I, Schiby G, Jacob-Hirsch J, Rechavi G, Crispino JD, Izraeli S.

Blood. 2013 Aug 8;122(6):988-98. doi: 10.1182/blood-2012-10-460998. Epub 2013 May 29.

45.

AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

Stankiewicz MJ, Crispino JD.

Leukemia. 2013 Jun;27(6):1339-47. doi: 10.1038/leu.2013.33. Epub 2013 Feb 5.

46.

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.

Malinge S, Thiollier C, Chlon TM, Doré LC, Diebold L, Bluteau O, Mabialah V, Vainchenker W, Dessen P, Winandy S, Mercher T, Crispino JD.

Blood. 2013 Mar 28;121(13):2440-51. doi: 10.1182/blood-2012-08-450627. Epub 2013 Jan 18.

47.

[Novel ETO2-GLIS2 fusion and therapeutic strategy in acute megakaryoblastic leukemia].

Thiollier C, Pflumio F, Ballerini P, Crispino JD, Bernard O, Mercher T.

Med Sci (Paris). 2012 Nov;28(11):1013-6. doi: 10.1051/medsci/20122811025. Epub 2012 Nov 12. French. No abstract available.

48.

BMP meets AML: induction of BMP signaling by a novel fusion gene promotes pediatric acute leukemia.

Crispino JD, Le Beau MM.

Cancer Cell. 2012 Nov 13;22(5):567-8. doi: 10.1016/j.ccr.2012.10.008.

49.

Combinatorial regulation of tissue specification by GATA and FOG factors.

Chlon TM, Crispino JD.

Development. 2012 Nov;139(21):3905-16. doi: 10.1242/dev.080440. Review.

50.

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T.

J Exp Med. 2012 Oct 22;209(11):2017-31. doi: 10.1084/jem.20121343. Epub 2012 Oct 8.

Supplemental Content

Loading ...
Support Center